Big Tech is pouring more than US$700b into AI infrastructure this year, and healthcare is one of the key testing grounds for ...
- Affinia Therapeutics, a private gene therapy firm, showcased its BAG3 DCM treatment at a major cardiology conference but remains unlisted for public investment. - The therapy targets a rare genetic ...
- Vylor VYLR+0.49% (VYLR) trades at 48x earnings despite generating only $1.2B in operating cash flow, far exceeding its ...
Morning Overview on MSN
Higher blood levels of a gut-made molecule tracked with faster cognitive decline in an Alzheimer’s study
People with more imidazole propionate in their blood lost cognitive ground faster over repeated testing, in a study of 1,196 ...
Take a drop of pond water and look at it under a microscope. There, you will find tiny green specks swimming toward the light ...
Vylor is a seed and crop genetics pure-play company. The company was formed in 2026 when it was spun off from Corteva. Vylor is a leader in the development of genetically modified seeds and other ...
Morning Overview on MSN
People most likely reached the Americas 20,000 to 14,000 years ago, a Kansas-led review concludes
Archaeologists have proposed dates for the first people in the Americas that span more than 100,000 years, from roughly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results